Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Douillard, J.-Y.
Right arrow Articles by Van Cutsem, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douillard, J.-Y.
Right arrow Articles by Van Cutsem, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:ii7-ii12, 2003
© 2003 European Society for Medical Oncology

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy

J.-Y. Douillard1,+, A. Sobrero2, C. Carnaghi3, P. Comella4, E. Díaz-Rubio5, A. Santoro3 and E. Van Cutsem6

1 Centre R Gauducheau, Nantes, France; 2 Ospedale S. Martino, Genova; 3 Istituto Clinico Humanitas, Rozzano; 4 Istitu Istituto Nazionale Tumori, Napoli, Italy; 5 Hospital Clínico Universitario San Carlos, Madrid, Spain; 6 University Hospital Gasthuisberg, Leuven, Belgium

Abstract

The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements. Through the biochemical modulation of 5-fluorouracil (5-FU) with folinic acid (FA), the use of infusional rather than bolus regimens and the combination of 5-FU/FA with other active agents (notably irinotecan), first-line response rates (RRs) of 40% can be achieved, with patients surviving up to 17 months. Significant benefits on survival are also seen with second-line chemotherapy. The question of how best to sequence combination chemotherapy was addressed in a recent trial in which patients were randomized to receive either an irinotecan-based combination with 5-FU/FA (FOLFIRI) followed by an oxaliplatin-based combination (FOLFOX), or the two regimens in the reverse order. In both arms, RRs were greater than 50% and median survival exceeded 20 months. The primary end point was time to progression after two lines of treatment, and this was not significantly different. However, the sequence FOLFIRI followed by FOLFOX appears preferable because of the better tolerability of FOLFIRI in first-line use. Use of the sequence FOLFIRI/FOLFOX is also supported by the greater chance of a second-line response with FOLFOX. Concern has been expressed about the safety of irinotecan combined with bolus 5-FU/FA. Infusional regimens have a better risk/benefit ratio than bolus regimens. However, the adverse event profile with both approaches is manageable, and irinotecan plus 5-FU/FA can be considered one standard of care in metastatic CRC.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
F. A. de Jong, D. F. S. Kehrer, R. H. J. Mathijssen, G.-J. Creemers, P. de Bruijn, R. H. N. van Schaik, A. S. Th. Planting, A. van der Gaast, F. A. L. M. Eskens, J. Th. P. Janssen, et al.
Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for UGT1A1*28 Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study
Oncologist, September 1, 2006; 11(8): 944 - 954.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Wasil and S. M. Lichtman
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Oncologist, September 1, 2005; 10(8): 602 - 612.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.